Management of post-subarachnoid hemorrhage vasospasm

Current Atherosclerosis Reports

Volumn 10, Issue 4, 2008, Pages 354-360

  Gump, William ^b   Laskowitz, Daniel T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1 MONOCLONAL ANTIBODY; ETIRACETAM; FLUDROCORTISONE; FOSPHENYTOIN SODIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; MONOCLONAL ANTIBODY; NICARDIPINE; NIMODIPINE; PAPAVERINE; PHENYTOIN; PLACEBO; SEMAPIMOD; SILDENAFIL; SIMVASTATIN; TS 011; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASODILATOR AGENT;

ANEURYSM SURGERY; BRAIN ANGIOGRAPHY; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; BRAIN ISCHEMIA; BRAIN PROTECTION; BRAIN VASOSPASM; CLINICAL FEATURE; CLINICAL TRIAL; COIL EMBOLIZATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DRUG CHOICE; DRUG MECHANISM; EPILEPSY; FLUID THERAPY; GENETIC PREDISPOSITION; HEART DISEASE; HEMODILUTION; HUMAN; HYPERTENSION; INAPPROPRIATE VASOPRESSIN SECRETION; INTRACRANIAL ANEURYSM; LASER ANGIOPLASTY; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUBARACHNOID HEMORRHAGE;

HUMANS; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

EID: 58649101807     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0054-7     Document Type: Review

References (53)

1. van Gijn J, Kerr RS, Rinkel GJ: Subarachnoid haemorrhage. Lancet 2007, 369: 306-318.
2. Kissela BM, SauerbeAk L, Woo D, et al.: Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke 2002, 33: 1321-1326.
3. Hunt WE, Hess RM: Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg 1968, 28: 14-20.
4. Fisher CM, Kistler JP, Davis JM: Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by CT scanning. Neurosurgery 1980, 6: 1-9.
5. Kistler JP, Crowell RM, Davis KR, et al.: The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: A prospective study. Neurology 1983, 33: 424-426.
6. Jane JA, Winn HR, Richardson AE: The natural history of intracranial aneurysms: Rebleeding rates during the acute and long term period and implication for surgical management. Clin Neurosurg 1977, 24: 176-184.
7. Haley EC, Kassell NF, Torner JC: The International Cooperative Study on the Timing of Aneurysm Surgery. The North American experience. Stroke 1992, 23: 205-214.
8. Molyneux A, Kerr R, Stratton I, et al.: International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised trial. Lancet 2002, 360: 1267-1274.
9. Molyneux AJ, Kerr RS, Yu LM, et al.; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group: International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: A randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005, 366: 809-817.
10. Rhoney DH, Tipps LB, Murry KR, et al.: Anticonvulsant prophylaxis and timing of seizures after aneurysmal subarachnoid hemorrhage. Neurology 2000, 55: 258-265.
11. Claassen J, Peery S, Kreiter KT, et al.: Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Neurology 2003, 60: 208-214.
12. Lin CL, Dumont AS, Lieu AS, et al.: Characterization of perioperative seizures and epilepsy following aneurysmal subarachnoid hemorrhage. J Neurosurg 2003, 99: 978-985.
13. Naidech AM, Kreiter KT, Janjua N, et al.: Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005, 36: 583-587.
14. Wang H, Gao J, Lassiter TF, et al.: Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 2006, 5: 71-78.
15. McGirt MJ, Blessing R, Nimjee SM, et al.: Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. Neurosurgery 2004, 54: 1369-1373.
16. Hasan D, Lindsay KW, Wijdicks EF, et al.: Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. Stroke 1989, 20: 1156-1161. 1156-1161.
17. Sakr YL, Ghosn I, Vincent JL: Cardiac manifestations after subarachnoid hemorrhage: A systematic review of the literature. Prog Cardiovasc Dis 2002, 45: 67-80.
18. Masuda T, Sato K, Yamamoto S, et al.: Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. Stroke 2002, 33: 1671-1676.
19. Mayer SA, Lin J, Homma S, et al.: Myocardial injury and left ventricular performance after subarachnoid hemorrhage. Stroke 1999, 30: 780-786.
20. Kassell NF, Sasaki T, Colohan AR, et al.: Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985, 16: 562-572.
21. Saqqur M, Zygun D, Demchuk A: Role of transcranial Doppler in neurocritical care. Crit Care Med 2007, 35(5 Suppl): S216-S223.
22. Grosset DG, Straiton J, McDonald I, et al.: Angiographic and Doppler diagnosis of cerebral artery vasospasm following subarachnoid haemorrhage. Br J Neurosurg 1993, 7: 291-298.
23. Dietrich HH, Dacey RG: Molecular keys to the problems of cerebral vasospasm. Neurosurgery 2000, 46: 517-530.
24. McGirt MJ, Lynch JR, Blessing R, et al.: Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after subarachnoid hemorrhage. Neurosurgery 2002, 51: 1128-1134.
25. Allen GS, Ahn HS, Preziosi TH, et al.: Cerebral arterial spasm-a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983, 308: 619-624.
26. Pickard JD, Murray GD, Illingworth R, et al.: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989, 298: 636-642.
27. Korenkov AI, Pahnke J, Frei K, et al.: Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev 2000, 23: 145-150.
28. Petruk KC, West M, Mohr G, et al.: Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988, 68: 505-517.
29. Haley EC, Kassell NF, Torner JC: A randomized trial of nicardipine in subarachnoid hemorrhage: Angiographic and transcranial Doppler ultrasound reports. A report of the Cooperative Aneurysm Study. J Neurosurg 1993, 78: 548-553.
30. Haley EC, Kassell NF, Torner JC: A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1993, 78: 537-547.
31. Mesis RG, Wang H, Lombard FW, et al.: Dissociation between vasospasm and functional improvement in a murine model of subarachnoid hemorrhage. Neurosurg Focus 2006, 21: E4.
32. Vajkoczy P, Meyer B, Weidauer S, et al.: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005, 103: 9-17.
33. Romner B, Reinstrup P: Triple H therapy after aneurysmal subarachnoid hemorrhage. A review. Acta Neurochir Suppl 2001, 77: 237-241.
34. Muench E, Horn P, Bauhuf C, et al.: Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. Crit Care Med 2007, 35: 1844-1851.
35. Badjatia N, Topcuoglu MA, Pryor JC, et al.: Preliminary experience with intra-arterial nicardipine as a treatment for cerebral vasospasm. AJNR Am J Neuroradiol 2004, 25: 819-826.
36. McGirt MJ, Lynch JR, Parra A, et al.: Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002, 33: 2950-2956.
37. Bulsara KR, Coates JR, Agrawal VK, et al.: Effect of combined simvastatin and cyclosporine compared with simvastatin alone on cerebral vasospasm after subarachnoid hemorrhage in a canine model. Neurosurg Focus 2006, 21: E11.
38. Lynch JR, Wang H, McGirt MJ, et al.: Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: Results of a pilot randomized clinical trial. Stroke 2005, 36: 2024-2026.
39. Tseng MY, Czosnyka M, Richards H, et al.: Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: A phase II randomized placebo-controlled trial. Stroke 2006, 37: 1627-1632.
40. Bowman G, Dixit S, Bonneau RH, et al.: Neutralizing antibody against interleukin-6 attenuates posthemorrhagic vasospasm in the rat femoral artery model. Neurosurgery 2004, 54: 719-725.
41. Orshal JM, Khalil RA: Reduced endothelial NOcGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension 2004, 43: 434-444.
42. Lin CL, Dumont AS, Calisaneller T, et al.: Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm. Surg Neurol 2005, 64: 201-205.
43. Lin CL, Kwan AL, Dumont AS, et al.: Attenuation of experimental subarachnoid hemorrhage-induced increases in circulating intercellular adhesion molecule-1 and cerebral vasospasm by the endothelin-converting enzyme inhibitor CGS 26303. J Neurosurg 2007, 106: 442-448.
44. Yatsushige H, Yamaguchi M, Zhou C, et al.: Role of c-Jun N-terminal kinase in cerebral vasospasm after experimental subarachnoid hemorrhage. Stroke 2005, 36: 1538-1543.
45. Hacein-Bey L, Harder DR, Meier HT, et al.: Reversal of delayed vasospasm by TS-011 in the dual hemorrhage dog model of subarachnoid hemorrhage. AJNR Am J Neuroradiol 2006, 27: 1350-1354.
46. Ozum U, Aslan A, Karadag O, et al.: Intracisternal versus intracarotid infusion of L-arginine in experimental cerebral vasospasm. J Clin Neurosci 2007, 14: 556-562.
47. Pluta RM, Afshar JK, Thompson BG, et al.: Increased cerebral blood flow but no reversal or prevention of vasospasm in response to L-arginine infusion after subarachnoid hemorrhage. J Neurosurg 2000, 92: 121-126.
48. Atalay B, Caner H, Cekinmez M, et al.: Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery 2006, 59: 1102-1108.
49. Lanterna LA, Ruigrok Y, Alexander S, et al.: Meta-analysis of APOE genotype and subarachnoid hemorrhage: Clinical outcome and delayed ischemia. Neurology 2007, 69: 766-775.
50. Gao J, Wang H, Sheng H, et al.: A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit Care 2006, 4: 25-31.
51. Laskowitz DT, Thekdi AD, Thekdi SD, et al.: Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 2001, 167: 74-85.
52. Lynch JR, Tang W, Wang H, et al.: APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003, 278: 48529-48533.
53. Laskowitz DT, Fillit H, Yeung N, et al.: Apolipoprotein E-derived peptides reduce CNS inflammation: Implications for therapy of neurological disease. Acta Neurol Scand Suppl 2006, 185: 15-20.